A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome


The purpose of this is study is to evaluate the effects of DCCR (diazoxide choline controlled release tablets) in children and adults with Prader-Willi syndrome.

Full Title of Study: “A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: May 1, 2020


  • Drug: DCCR
    • Once daily oral administration
  • Drug: Placebo for DCCR
    • Once daily oral administration

Arms, Groups and Cohorts

  • Experimental: DCCR
    • 75 – 450 mg DCCR
  • Placebo Comparator: Placebo
    • 75 – 450 mg placebo for DCCR

Clinical Trial Outcome Measures

Primary Measures

  • Hyperphagia Score
    • Time Frame: Baseline to Week 13
    • Change in hyperphagia-related behavior as measured by total score of a Hyperphagia Questionnaire

Secondary Measures

  • Body fat mass (DXA)
    • Time Frame: Baseline to Week 13
    • Change in Body Fat Mass from Baseline to Week 13
  • CGI-I
    • Time Frame: at Week 13
    • Clinical Global Impression of Improvement
  • Caregiver GI-C
    • Time Frame: at Week 13
    • Caregiver Global Impression of Change

Participating in This Clinical Trial

Inclusion Criteria

  • Provide voluntary, written informed consent (parent(s) / legal guardian(s) of patient); provide voluntary, written assent (patients, as appropriate)
  • Genetically-confirmed Prader-Willi syndrome and hyperphagic
  • In a stable care setting for at least 6 months prior to Visit 1
  • Caregiver must have been caring for the patient for at least 6 months prior to Visit 1

Exclusion Criteria

  • Have participated in an interventional clinical study (i.e., investigational drug or device, approved drugs or device evaluated for unapproved use) within prior 3 months
  • Positive urine pregnancy test (in females of child-bearing potential) or females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 30 days after study participation
  • Any other known disease and/or condition, which would prevent, in the opinion of the Investigator, the patient from completing all study visits and assessments required by the protocol

Gender Eligibility: All

Minimum Age: 4 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Soleno Therapeutics, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.